Otsuka Holdings Co., Ltd.: Schizophrenia trials

The registry lists 116 Schizophrenia studies with Otsuka Holdings Co., Ltd. as lead sponsor. 2 are open to participants now and 61 have results posted.

Phase 1 35Phase 2 14Phase 3 51Phase 4 12No phase 9(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.CompletedNCT00325689Phase 4
• Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)CompletedNCT00304655Phase 4
• SWitching to Abilify Trial (SWAT)CompletedNCT00304616Phase 4
• A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic PatientsCompletedNCT00300846Phase 4
• A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric PracticesCompletedNCT00292409Phase 3
• Aripiprazole in the Treatment of Acutely Relapsed Patients With SchizophreniaCompletedNCT00283179Phase 3
• A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric PracticesCompletedNCT00237939Phase 3
• Schizophrenia Trial of AripiprazoleCompletedNCT00237913Phase 3
• A Switch Study of BMS-337039 in Schizophrenic Out-patientsCompletedNCT00232687Phase 4
• Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar DisorderCompletedNCT00216723
• Efficacy and Safety Study of Aripiprazole to Treat SchizophreniaCompletedNCT00202007Phase 2
• Aripiprazole Oral Acceptability TrialCompletedNCT00101569Phase 3
• Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective DisorderCompletedNCT00095524Phase 3
• Study of Three Doses of Aripiprazole in Patients With Acute SchizophreniaCompletedNCT00080327Phase 4
• Broad Effectiveness: Study With AripiprazoleCompletedNCT00036361Phase 3
• Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic DisordersCompletedNCT00036127Phase 2/3